ST1535 – 5 mg

Brand:
Cayman
CAS:
496955-42-1
Storage:
-20
UN-No:
Non-Hazardous - /

ST1535 is an adenosine A2A receptor antagonist.{58030} It is selective for adenosine A2A over A1 receptors (Kis = 2.3 and 107 nM, respectively, in radioligand binding assays). ST1535 inhibits agonist-induced production of cAMP in CHO cells expressing adenosine A2A receptors (IC50 = 353 nM). In vivo, ST1535 (10 and 20 mg/kg) reduces haloperidol-induced catalepsy in mice. It reduces the number of jaw tremors in a rat model of Parkinsonian jaw tremors induced by tacrine (Item No. 70240).{58031} ST1535 (20 and 40 mg/kg) increases locomotor activity and reverses motor disabilities in a marmoset model of MPTP-induced Parkinson’s disease.{58032}  

 

Available on backorder

SKU: 10611 - 5 mg Category:

Description

An adenosine A2A receptor antagonist; selective for adenosine A2A over A1 receptors (Kis = 2.3 and 107 nM, respectively, in radioligand binding assays); inhibits agonist-induced production of cAMP in CHO cells expressing adenosine A2A receptors (IC50 = 353 nM); reduces haloperidol-induced catalepsy in mice at 10 and 20 mg/kg; reduces the number of jaw tremors in a rat model of tacrine-induced Parkinsonian jaw tremors; increases locomotor activity and reverses motor disabilities in a marmoset model of MPTP-induced Parkinson’s disease at 20 and 40 mg/kg


Formal name: 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine

Synonyms: 

Molecular weight: 272.3

CAS: 496955-42-1

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease